Beta Bionics, Inc. Income Statement
BBNX / Health Care|3 years of annual SEC 10-K data (FY2023-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
Beta Bionics, Inc. reported $100M in revenue and $73M in net loss for FY2025. Revenue has grown at a 189.1% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $100.3M | $65.1M | $12.0M |
| Cost of Revenue | $44.7M | $29.2M | $5.7M |
| Gross Profit | $55.5M | $35.9M | $6.3M |
| SG&A Expense | $31.0M | $17.9M | $12.2M |
| R&D Expense | $34.8M | $26.2M | $17.9M |
| Operating Income | -$71.7M | -$45.3M | -$35.9M |
| Income Tax | $0 | $0 | - |
| Net Income | -$73.2M | -$54.8M | -$44.1M |
| EPS (Basic) | -$8.60 | -$8.60 | -$8.31 |
| EPS (Diluted) | -$8.60 | -$8.60 | -$8.31 |
| Shares Outstanding | 6.7M | 6.4M | 5.3M |
| Gross Margin | 55.4% | 55.1% | 52.6% |
| Operating Margin | -71.5% | -69.5% | - |
| Profit Margin | -73.0% | -84.1% | - |